Check out the latest articles in our Investment Trusts portal

Less Ads, More Data, More Tools Register for FREE

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Thu, 21st Nov 2019 12:56

(Alliance News) - Faron Pharmaceuticals Oy on Thursday said it has applied to list is shares on Nasdaq First North Growth Market.

Faron's shares are currently traded on London's AIM market via depositary interest, and these were up 9.8% at 195.50 pence on Thursday afternoon.

Nasdaq First North Growth is a multilateral trading facility and is operated by Nasdaq Helsinki Ltd, it is intended to help Nordic and international companies to increase investor visibility in preparation for a listing on the regulated Nasdaq Main Market.

Should the application prove successful, clinical stage biopharmaceutical firm Faron expects its first day of Nasdaq First North trading to be December 3.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related Shares

More News

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

13 Jan 20 11:54

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

30 Dec 19 15:39

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

30 Dec 19 10:56

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

11 Dec 19 13:42

Login to your account

Don't have an account? Click here to register.